Soligenix's Clinical Results From HyBryte Compatibility Study For Cutaneous T-Cell Lymphoma Published In JEADV Clinical Practice
Soligenix's Clinical Results From HyBryte Compatibility Study For Cutaneous T-Cell Lymphoma Published In JEADV Clinical Practice
Soligenix的皮膚T細胞淋巴瘤Hybryte兼容性研究的臨床結果發表在JEADV臨床實踐中
The treatment response results of 22% following 8 weeks of twice weekly HyBryte therapy reinforces and confirms the results of the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial published in the Journal of the American Medical Association (JAMA) Dermatology, despite the fact that patients in Study HPN-CTCL-02 were specifically selected to have more extensive disease consistent with its potential commercial use.
儘管在 HPN-CTCL-02 研究中特別挑選的患者患有與其潛在商業用途相一致的更廣泛疾病，但每週兩次 Hybryte 療法 8 周後的治療反應結果爲 22%，這強化並證實了發表在《美國醫學會雜誌》（JAMA）皮膚病學雜誌上的 3 期 FLASH（熒光激活合成金絲桃素）試驗的結果。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。